Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (327)	5/12/1999 7:46:00 PM
From: Roger Cranwill	Respond to of 656

There has been quite a lot of interest in the plant derived female estrogen replacement from the public, even though Premarin is derived from a natural source (PREgnant MAre's urINe). Ayerest has pretty much had a lock on the hormonal estrogen replacement market for 30 years (there were generic substitutes for a while, but were taken off the market because they weren't identical in composition to the original). Whether it will go over is another thing-there are other plant derived hormonal products on the market, but none come within 1-2% of the volume of prescriptions given out for Premarin. I think new factors come in to play, however, one being the herbal market-its making big inroads into the medical marketplace, and if the product is perceived as more "natural" (to the public, substitute the word "safer"), the drug may pick up a serious market share.